英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
GZD824 Dimesylate
|
1421783-64-3 |
GZD824DIMESYLATE
|
GZD824二甲磺酸盐;耐克替尼甲磺酸盐;GZD824DIMESYLATE;GZD824甲磺酸盐
|
C31H35F3N6O7S2 |
724.77081 | |
GW441756
|
504433-23-2 |
GW441756
|
1,3-二氢-3-[(1-甲基-1H-吲哚-3-基)亚甲基]-2H-吡咯并[3,2-b]吡啶-2-酮;GW441756>98%;GW 441756;GW-441756;1,3-二氢-3-[(1-甲基-1H-吲哚-3-基)亚甲基]-2H-吡咯并[3,2-B]吡啶-2-酮;3-[(1-METHYLINDOL-3-YL)METHYLIDENE]-1H-PYRROLO[3,2-B]PYRIDIN-2-ONE;HYDROCHLORIDE;CS-1085
|
C17H13N3O |
275.30462 | |
GSK 4716
|
101574-65-6 |
GSK 4716
|
4-羟基苯甲酸2-[[4-(1-甲基乙基)苯基]亚甲基]肼;CS-1084
|
C10H14N2O- |
282.33702 | |
GF 109203X
|
133052-90-1 |
GF1923X
|
GF 109203X盐酸盐 ≥95%;3-[1-[3-(二甲氨基)丙基]1H-吲哚-3-基]-4-(吲哚-3-基)1H-吡咯-2,5二酮
|
C25H24N4O2 |
412.48 | 603-702-0 |
Otenabant
|
686344-29-6 |
奥替那班
|
1-[9-(4-氯苯基)-8-(2-氯苯基)-9H-嘌呤-6-基]-4-乙基氨基哌啶-4-甲酰胺;奥替那班;CS-1072;CP 945598;OTENABANT;CP945598;CP 945598;CP-945598;CP945599
|
C25H25Cl2N7O |
510.42 | |
CNX-1351
|
1276105-89-5 |
CNX1351
|
CS-1069;1-[4-[[2-(1H-吲唑-4-基)-4-(4-吗啉基)噻吩并[3,2-D]嘧啶-6-基]甲基]-1-哌嗪基]-6-甲基-5-庚烯-1,4-二酮;CNX-1351;CNX 1351;CNX1351
|
C30H35N7O3S |
573.709 | |
CFTRinh-172
|
307510-92-5 |
CFTRinh-172
|
3-[(3-三氟甲基)苯基]-5-[(4-羧基苯基)亚甲基]-2-硫代-4-噻唑烷酮;3-[(3-三氟甲基)苯基]-5-[(4-羧基苯基)亚甲基]-2-硫代-4-噻唑烷酮;CS-1067;CFTR INHIBITOR-172;CFTRINH-172
|
C18H10F3NO3S2 |
409.4 | |
Cebranopadol
|
863513-91-1 |
CEBRANOPADOL
|
|
C24H27FN2O |
378.4823832 | |
BMS-863233 (XL-413)
|
1169562-71-3 |
XL413 (BMS-863233)
|
8-氯-2-(2S)-2-吡咯烷基苯并呋喃并[3,2-D]嘧啶-4(3H)-酮盐酸盐;XL413(BMS-863233);CS-1062;BMS-863233;BMS863233;BMS 863233;XL-413;XL413;XL 413.;XL413.HCL
|
C14H13Cl2N3O2 |
326.17792 | |
Alvelestat
|
848141-11-7 |
ALVELESTAT
|
AZD9668;AZD-9668;AZD 9668;CS-1060
|
C25H22F3N5O4S |
545.5334896 | |
Tavaborole
|
174671-46-6 |
他伐硼罗
|
他伐保洛;1-羟基-5-氟-2,1-苯并氧杂环戊硼烷;5-氟-1,3-二氢-1-羟基-2,1-苯并氧杂硼戊环;他伐硼罗;2-羟基甲基-5-氟苯硼酸半酯
|
C7H6BO2F |
151.93074 | |
CFTR-Inhibitor-II
|
328541-79-3 |
GLYH 11
|
|
C19H15Br2N3O3 |
493.1487 | |
TUG-770
|
1402601-82-4 |
TUG-77
|
TUG-770;4-[2-[2-(Cyanomethyl)phenyl]ethynyl]-2-fluorobenzenepropanoic acid;4-[2-[2-(Cyanomethyl)phenyl]ethynyl]-2-fluorobenzenepropanoic acid TUG-770;3-(4-((2-(Cyanomethyl)phenyl)ethynyl)-2-fluorophenyl)propanoic acid
|
|||
Glasdegib
|
1095173-27-5 |
Glasdegib(PF-4449913)
|
Glasdegib;CS-1041;N-[(2R,4R)-2-(1H-苯并咪唑-2-基)-1-甲基-4-哌啶基]-N'-(4-氰基苯基)脲;PF04449913;PF 04449913
|
C21H22N6O |
374.43898 | |
oMbrabulin
|
181816-48-8 |
奥瑞布林
|
CS-1038;(2S)-2-氨基-3-羟基-N-[2-甲氧基-5-[(1Z)-2-(3,4,5-三甲氧基苯基)乙烯基]苯基]丙酰胺;AVE8062;AVE8062A;AC7700;AVE-8062;AVE-8062A;AC-7700;AVE 8062;AVE 8062A;AC 7700;AVE8062;AC-7700;CS-39-L-SER.HCL;AVE-8062A;AVE-8062;RPR-258062A.;奥瑞布林
|
C21H26N2O6 |
402.44 | |
LGX 818
|
1269440-17-6 |
Encorafenib (LGX818)
|
CS-1037;(S)-[1-[[4-[3-[5-氯-2-氟-3-(甲基磺酰胺基)苯基]-1-异丙基-1H-吡唑-4-基]嘧啶-2-基]氨基]丙-2-基]氨基甲酸甲酯;LGX 818;LGX-818;LGX818;ENCORAFENIB;LGX818;LGX-818
|
C22H27ClFN7O4S |
540.0106832 | |
Atglistatin
|
1469924-27-3 |
ATGLISTATIN
|
CS-1024;1'-联苯]-3-基]-N;N'-[4'-(二甲基氨基)[1;3-(4'-(DIMETHYLAMINO)BIPHENYL-3-YL)-1,1-DIMETHYLUREA;N'-[4'-(二甲基氨基)[1,1'-联苯]-3-基]-N,N-二甲基脲;1,1-二甲基-3-[4'-(二甲氨基)-联苯-3-基]脲
|
C17H21N3O |
283.36814 | 200-256-5 |
AR-A 014418
|
487021-52-3 |
AR-A 14418
|
CS-1021;N-(4-甲氧基苄基)-N'-(5-硝基-1,3-噻唑-2-基)脲;AR-AO 14418;AR 0133418;AR 014418;GSK 3Β INHIBITOR;AR 0133418;GSK 3Β INHIBITOR VIII;AR 014418;GSK-3BETA 抑制剂 VIII
|
C12H12N4O4S |
308.317 | |
S1RA
|
878141-96-9 |
S1RA
|
4-(2-{[5-Methyl-1-(2-naphthyl)-1H-pyrazol-3-yl]oxy}ethyl)morpholi ne;S1RA;4-[2-[[5-Methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine;4-[2-[[5-Methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine S1RA;S1RA 4-[2-[[5-Methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]morpholine;S1RA, >=98%;S1RA, 878141-96-9;4-(2-((5-Methyl-1-(naphthalen-2-yl)-1H-pyrazol-3-yl)oxy)ethyl)morpholine
|
|||
TGR5
|
1197300-24-5 |
TGR5
|
CS-1017;3-(2-CHLOROPHENYL)-N-(4-CHLOROPHENYL)-N,5-DIMETHYLISOXAZOLE-4-CARBOXAMIDE;3-(2-氯苯基)-N-(4-氯苯基)-N,5-二甲基-4-异恶唑甲酰胺;3-(2-氯苯基)-N-(4-氯苯基)-N,5-二甲基-4-异噁唑羧酰胺
|
C18H14Cl2N2O2 |
361.22196 | 200-256-5 |